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Abstract
Background: Drug resistance to anti-malarials is a major public health problem worldwide. This study aimed at
establishing the efficacy of artemether-lumefantrine (ACT) in Igombe-Mwanza, north-western Tanzania after a few
years of ACT use, and establish the prevalence of mutations in key targets for artemisinin, chloroquine and
sulphadoxine/pyrimetamine (SP) drugs.
Methods: A prospective single cohort study was conducted at Igombe health centre using artemether-
lumefantrine combination therapy between February 2010 and March 2011. The follow-up period was 28 days and
outcome measures were according to WHO guidelines. Blood was collected on Whatman filter paper for DNA
analysis. DNA extraction was done using TRIS-EDTA method, and mutations in Pfcrt, Pfmdr1, Pfdhfr, Pfdhps and
Pfatp6 were detected using PCR-RFLP methods established previously.
Results: A total of 103 patients completed the 28 days follow-up. The mean haemoglobin was 8.9 g/dl (range 5.0
to 14.5 g/dl) and mean parasite density was 5,608 parasites/μl. Average parasite clearance time was 34.7 hours and
all patients cleared the parasites by day 3. There was no early treatment failure in this study. Late clinical failure
was seen in three (2.9%) patients and late parasitological failure (LPF) was seen in two (1.9%). PCR-corrected LPF
was 1% and adequate clinical and parasitological response was 96%. The majority of parasites have wild type
alleles on pfcrt 76 and pfmdr1 86 positions being 87.8% and 93.7% respectively. Mutant parasites predominated at
pfdhfr gene at the main three positions 108, 51 and 59 with prevalence of 94.8%, 75.3% and 82.5% respectively.
Post-treatment parasites had more wild types of pfdhps at position 437 and 540 than pre-treatment parasites. No
mutation was seen in pfatp6 769 in re-infecting or recrudescing parasites.
Conclusion: The efficacy of artemether-lumefantrine for treatment of uncomplicated malaria is still high in the
study area although the rate of re-infection is higher than previously reported. Parasite clearance after 48 hours
was lower compared to previous studies. The prevalence of wild type allele pfcrt 76 K and pfmdr1 86 N was high
in the study area while markers for SP resistance is still high. Artemether-lumefantrine may be selecting for wild
type alleles on both positions (437 and 540) of pfdhps.
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Drug resistance to anti-malarials is a major public health
problem worldwide [1]. In 2006, Tanzania changed policy
from use of sulphadoxine-pyrimethamine (SP) as a first-
line drug for treatment of uncomplicated malaria to arte-
mether-lumefantrine combination therapy (AL) [2]. This
was a second change following the first change from
chloroquine (CQ) to SP in 2001 [3,4]. This milestone is
similar in many African countries where malaria is ende-
mic. A change of anti-malarial drug policy has been
derived by development of drug resistance to commonly
used drugs by the Plasmodium parasites, especially Plas-
modium falciparum which causes more than 90% of infec-
tion in sub-Saharan Africa. Although there are reports of
decreasing paediatric malaria infection [5,6] and burden of
malaria [1]; malaria is still a major public health disease
causing 243 million cases every year, of which over 85%
are in Africa. Malaria led to 863,000 deaths in 2008 and
89% of them occurred in the sub-Saharan Africa region
[1]. Data from the field are now reporting emergence of
what is referred to as artemisinin resistance due to
increased number of parasites, which shows delayed clear-
ance from blood circulation on artemisinin combination
therapy (ACT) [7]. Clinical trials carried out so far in
Africa shows high efficacy of AL combination therapy
[8-11]. Hunt et al, 2009 reports that analysis of studies in
East Africa shows that the parasites were being controlled
less well by the artemisinin component of ACT in 2007/
2008 studies than in 2005/2006 [12]. As these reports are
coming up, the mechanism of action of artemisinin is not
known yet, a few target genes have been suggested with
inconclusive findings [13-16]. Treatment with AL has led
to selection of wild type alleles at molecular markers for
CQ resistance (pfcrt 76 K and pfmdr1 86 N) with a conco-
mitant reduction in susceptibility to lumefantrine [17].
Even before introduction of AL, re-emergence of wild
types for pfcrt has been reported in Malawi with restored
sensitivity to CQ [18,19]. It is not known whether it is the
use of lumefantrine, absence of CQ in the field or both
factors acting in synergy that leads to selection of CQ sus-
ceptible parasites. Tanzania is a country that has signifi-
cantly minimized the use of CQ for about 10 years now
but continues to use SP for IPTp (intermittent presump-
tive treatment in pregnancy). In such a situation there is a
need to continue monitoring the efficacy of AL in endemic
areas and prevalence of molecular markers for drug resis-
tance so as to give evidence-based data to national malaria
control programmes. This study aimed at establishing the
efficacy of AL in Igombe, Mwanza, north-western Tanza-
nia, after a few years of AL use and establish the preva-
lence of mutations in key targets for artemisinin,
chloroquine and sulphadoxine/pyrimetamine (SP) drugs.
Methods
Study area and design
This was an interventional prospective single cohort
study conducted at Igombe health centre in the vicinity
of Mwanza city in Tanzania. In this area malaria is
mesoendemic and the catchment area for Igombe health
centre is a semi-urban, with a population of around
40,000 inhabitants.
Recruitment of patients
Patients with fever, aged between six and 60 months
who attended the clinic during the study periods
(between February 2010 and July 2010 and between
October 2010 and March 2011) were screened for
malaria parasites. Detailed medical history, clinical
examination and both thick and thin blood films were
done after obtaining an informed consent from the par-
ents or guardian. Recruitment was based on inclusion
criteria set by WHO [20] (parasitaemia between 2,000
and 200,000 asexual stage parasites/μl, axillary tempera-
ture ≥ 37.5°C). Patients must not have history of anti-
malarial use in the last 14 days, no signs of severe
malaria or danger signs and no other infections.
Treatment of patients and follow-up
A six-dose regimen of artemether-lumefantrine (Co-
artem
®, Novartis, Basel, Switzerland) was used to treat
recruited patients. A first dose was given as a direct
observed therapy (DOT) and the next doses was sup-
plied to the parents/caretakers for giving to patients at
eight hours from the time of the first dose and morning
and evenings of successive two days. For patients weigh-
ing from 5 kg to less than 14 kg a single tablet (20 mg/
120 mg artemether/lumefantrine) was given, those from
15 kg to less than 24 kg received two tablets, those with
25 to less than 34 kg received three tablets. Patients
with fever and axillary body temperature ≥ 38.5°C were
given paracetamol and those with anaemia (Hb between
5 and 9 g/dl) were given haematinics. If a patient vom-
ited the treatment drug within 30 minutes the dose was
repeated and those who vomited more than once were
excluded from the study and changed to parenteral qui-
nine. Patients were followed up on days 1, 2, 3, 7, 14, 21
and 28. Patients were reminded of their visiting dates by
mobile phones if the parents owned one, or through the
10 cell-leaders’ phones; those who did not turn up on
the scheduled days were visited by a member of the
research team. A patient was withdrawn from the study
if the follow-up was not complete and could not be
traced the following day and these included patients
w h ot r a v e l l e dt oo t h e rp l a c e s .A l s ou s eo fo t h e ra n t i -
malarial drugs or non-compliance especially to the
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from the study.
According to WHO in vivo test protocol [20] the out-
comes were classified into early treatment failure (ETF),
late clinical failure (LCF), late parasitological failure
(LPF) and adequate clinical and parasitological response
(ACPR).
ETF was defined as the occurrence of one of the fol-
lowing signs: signs of severe disease or danger signs on
day 1, 2 or 3 with parasitaemia, level of parasitaemia on
day 2 that exceeded that on day 0, an axillary tempera-
t u r eo f3 7 . 5 ° Co rh i g h e ro nd a y3i nt h ep r e s e n c eo f
parasitaemia or a level of parasitaemia on day 3 that was
at least 25% of the level at time of enrolment.
LCF was defined as the occurrence (to patients who
did not have ETF) of one of the following during days 4
to 28: danger signs, severe malaria or an axillary tem-
p e r a t u r eo f3 7 . 5 ° Co rh i g h e ri nt h ep r e s e n c eo f
parasitaemia.
LPF was defined as presence of parasitaemia on any
day from day 7 to day 28 without signs of severe disease
or fever and not previously meeting criteria of ETF or
LCF
ACPR was defined as absence of parasitaemia on day
28 irrespective of axillary temperature without pre-
viously meeting any of the criteria of ETF, LTF or LPF
Ethical clearance
The study was approved by the Joint Weill-Bugando
ethical clearance committee and informed consent was
obtained from the parents/guardians of all patients.
Blood sample collection and haemoglobin estimation
On day of recruitment finger prick was done aseptically
and blood was spotted on Whatman no 1 filter paper,
thick and thin blood smears were done and stained with
Giemsa. A venopunture was done and 3 ml of blood
was taken in EDTA vacutainer for full blood count
(including haemoglobin estimation) using Cell Dyn 3700
machine (Abbot Laboratories USA). On follow-up only,
finger prick blood was collected and spotted on filter
papers.
Molecular analysis
DNA was extracted from dried blood spot on filter
paper using TRIS-EDTA method [21] and stored at -20°
C until future use. Mutations on pfcrt position 76 were
determined using primers and RFLP performed as
explained elsewhere [22]. Pfmdr1 gene was also ampli-
fied by nested PCR and RFLP done according to proto-
cols published before [23]. For pfdhfr,o u t e rP C Rw a s
done using primer pfdhfr1 and pfdhfr2 and nested PCR
was done using primer pfdhfr3 and pfdhfr4 for position
108 and pfdhfr5 and pfdhfr6 for nested reaction on
position 51 and 59 (see Tables 1 and 2 for PCR primers
and programmes). The pfdhps gene covering positions
540 and 437 was amplified and digested using primers
and protocols published previously [24]. For pfatp6 posi-
tions 263 and 769, PCR-RFLP methods described by
Kamugisha et al, 2011 and Sisowath et al,2 0 0 7w e r e
used [25,26]. All PCR products and restriction digests
were separated by agarose gel electrophoresis and visua-
lized using UV trans-illuminator. Distinction between
re-infection and recrudescence was done using PCR and
RFLP on msp-2 gene as previously described [27]. Data
were analysed using SPSS version 17.
Results
A total of 1,040 children under five years of age, with
fever, were screened for malaria parasites during the
study period. Five hundred and seventy six (55.4%) were
found positive for malaria parasites but only 108 met
the inclusion criteria and were recruited (Figure 1). Five
patients could not complete the study, three of these
were lost to follow-up while one was referred due to
severe vomiting (vomited the drug twice) and another
patient was not compliant as he did not take the dose at
eight hours. Therefore 103 patients completed the 28
days follow-up and were analysed.
Males were 52 (51.5%) and females were 51 (49.5%)
and the average age was 38.7 months. The mean haemo-
globin was 8.9 g/dl (range 5.0 to 14.5 g/dl), and mean
parasite density was 5,608 parasites/μl (ranging from
2,000 to 56,800 parasites/μl).
Average parasite clearance time was 34.7 hours, 70
(68%) cleared parasites within the first 24 hours and
cumulatively 91 (88.4%) patients had cleared the para-
sites at 48 hours. The remaining 12 (11.7%) patients had
positive blood slide at day 2 and they were all cleared of
parasites by day 3 (Figure 2). Only one patient had fever
on day 2 and others had fever resolution within the first
24 hours.
Table 1 Primers used for pfdhfr amplification
Name Sequence
Pfdhfr1(outer
forward)
5’-ATG ATG GAA CAA GTC TGC GAC-3’
Pfdhfr2(outer
reverse)
5’-C TTG ATA AAC AAC GGA ACC TCC-3’
Pfdhfr3(nested
forward)
5’-ACT ACA CAT TTA GAG GTC TAG G-3’
Pfdhfr4(nested
reverse)
5’-GG TTC TAG ACA ATA TAA CAT TTA TCC-3’
Pfdhfr5(nested
forward)
5’-GCC ATA TGT GCA TGT TGT AAG GTT GAA AG-
3’
Pfdhfr6(nested
reverse)
5’-CAT ATT TTG ATT CAT TCA CAT ATG TTG TAA
CTG CTC-3’
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three (2.9%) patients, LPF was seen in two (1.9%) and
ACPR was achieved in 98 (95.1%) patients before cor-
rection with PCR. PCR corrected LPF was 1% and
ACPR was 96% (Table 3).
A high number of subpatent infections were detected
by PCR (while looking at the drug resistance markers)
but not microscopy on both day 14 and day 28 raising
the prevalence to 15 (14.6%) and 13 (12.6%) respectively.
All subpatent infections were due to re-infections as
shown by different msp2 patterns.
Molecular markers for drug resistance
Pfcrt 76 position
A total of 90 samples were successfully amplified at
position 76 of pfcrt gene (success rate 87.4%) and
among these, the majority 80 (88.9%) were wild type
and only 10 (11.1%) were mutants. On follow-up sam-
ples, after treatment with AL, 12 samples were success-
fully amplified on day 14 and 28, of which a majority,
eight (66.7%), were wild type alleles and four (33.3%)
were mutant alleles. The difference between pre-treat-
ment samples and re-infections could not be shown to
be significant (Table 4).
Pfmdr1 86 position
At this position the wild type were higher, 89 (93.7%)
(including 85 pure wild types and four mixed, with wild
types dominating) and pure mutants were only six
(6.3%). Among the 19 successfully amplified post-treat-
ment samples, the wild type alleles were still in majority
at 11 (57.9%) but the proportion of mutants had
increased to 42.1%, which is a significant change (Table
4). All mutants in post-treatment samples did not come
from same patients with mutation at day 0.
Pfdhfr position 108, 51 and 59
For pfdhfr, successful amplification was achieved in 97
samples (success rate 97.2%). At position 108, 92
(94.8%) were mutant while four (4.3%) were wild type
and one (1.1%) was a mixed infection.
At position 51, the majority 73 (75.3%) were mutant
w h i l e1 2( 1 2 . 4 % )w e r ew i l dt y p ea n dt h eo t h e r1 2
(12.4%) were mixed with more mutants.
At position 59, 80 (82.5%) were mutant and nine
(9.3%) were wild type, while eight (8.2%) were mixed
with more mutants. The prevalence of triple mutants in
pfdhfr gene in pre-treatment samples was high with 59
samples (64.1%) while 27 (29.4%) had double mutation
with various combinations as illustrated in Table 5.
In post-treatment samples, mutants were predominant
b u ta tal o w e rp e r c e n t a g et h a na td a y0 :2 1 / 2 9( 7 4 . 2 % ) ,
20/29 (69%) and 15/29 (51.7%) on position 108, 51 and
59 respectively. In the post-treatment samples the triple
mutants were 13/29 (44.8%) and double mutants were
7/29 (24.1%) (Table 5). About eleven patients (47.8%)
were mutants in both pre-and post-treatment samples.
Pfdhps gene position 540 and 437
A total of 95 samples were successfully amplified at
position 540 and 66 (69.5%) were mutants, while 15
(15.8%) were wild type and 14 (14.7%) were mixed with
more mutants. At pfdhps 437, 96 samples were success-
fully amplified and 71 (74.0%) were mutants while 15
(15.6%) were wild type and 10 (10.4%) were mixed (with
mutants predominating). Double mutants in pfdhps
were 65 (68.4%) out of 95 samples, which amplified at
both positions. With the exception of one sample, all
mutants at position 540 were also mutants at position
437. There were more wild types at both positions in
pfdhps in the follow-up samples at day 14 and 28 after
treatment with ACT. Prevalence of wild types were 10/
17 (58.8%) and 13/21 (61.9%) at positions 437 and 540
respectively.
Pfatp6 position 263 and 769
There was no mutation in pfatp6 at position 263 in
either pre-treatment or post-treatment samples. At posi-
tion 769, mutations were screened only in re-infection
and recrudescing parasites and no mutation was
detected in these follow-up samples.
Discussion
The efficacy of AL in this study area was high at 95.1%
(PCR uncorrected) and 96% PCR corrected. This is simi-
lar to what has been found in other places of Tanzania
and Sub-Saharan Africa in general where cure rates ran-
ged from 96 to 100 in children [8-11,28]. The
Table 2 Programme used for pfdhfr amplification
Name PCR programme
Outer 94°C 3 min; 5 cycles:94°C 30 sec, 56°C 30 sec, 72°C 45 sec; 8 cycles: 92°C 30 sec, 55°C 30 sec, 72°C 45 sec; 12 cycles: 92°C 30 sec,
53°C 30 sec, 72°C 45 sec; 18 cycles: 92°C 30 sec, 50°C 30 sec, 72°C 45 sec; 16°C hold
Nested
(pfdhfr3
+pfdhfr4)
94°C 3 min; 30 cycles:94°C 1 min, 50°C 1 min, 72°C 1 min; 72°C 10 min; 4°C hold
Nested
(pfdhfr5
+pfdhfr6)
94°C 3 min; 30 cycles: 94°C 1 min, 55°C 1 min, 72°C 1 min; 72°C 10 min; 4°C hold
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pared to the findings in the above studies. However, a
more recent study, Ngasala et al, showed similar high
frequencies of LPF as shown here [29]. The meeting
proceedings reported by Hunt et al [12], presented evi-
dence of parasites in East Africa being less well con-
trolled in 2007/2008 studies compared to studies in
2005/2006. This may be the beginning of what is
3 patients lost to follow up
Day 14 (n=102), blood slide, dried blood spot
Day 21, (n=103), blood slide, dried blood spot
Day 28 (n=103), blood slide, dried blood spot
Day 2 (n=106), Blood slide
Day 3 (n=106), Blood slide
Day 7 (n=105), Blood slide, dried blood spot
Parasite count between 2000 to 
200,000/μl, no severe malaria, P. 
falciparum monoinfection (n=108) Included
Not meeting inclusion criteria 
(n=468) excluded
Day 1 (n=107), Blood slide
Blood slide positive for malaria 
parasites (n=576)
Blood slide negative for malaria parasites 
(n=464). Not recruited
Screened patients (n=1040)
1 patient excluded due to vomiting
1 patient excluded due non 
compliance
1 patient lost to follow up
1 patient who missed day 14 
returned on day 21
Figure 1 Patient recruitment and follow-up for 28 days in Igombe.
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tion therapies seen in South-east Asia [7]. In this study
recrudescence was low 1%. The mean parasite clearance
time in this study was 34.7 hours, which is consistent
with what was reported in 2005[8]. The percentage of
patients that had cleared the parasites by 48 hours was
lower compared to previous studies; this may be an
indicator of emergence of the resistant, dormant para-
sites reported in South-east Asia. The fact that no para-
sites were extended beyond day 3 shows that this ACT
is still more efficacious in Africa than has been seen in
South-east Asia. This may be explained by proper use of
ACT and relatively short time of use compared to
South-east Asia. The main combination in South-east
Asia is artemisinin-mefloquine, which may explain some
of the difference.
The prevalence of parasites with wild type alleles (pfcrt
76 K and pfmdr1 8 6 N )i sh i g hi nt h i ss t u d ya r e a
compared to other studies done previously in Tanzania.
This is a good indicator of return of CQ-sensitive para-
sites as was shown in Malawi study where Laufer et al,
found good in vivo sensitivity to CQ following a study
that revealed decline in mutants (pfcrt76T) at this posi-
tion [19]. The findings in this study could be due to
both proper control of CQ [30] or the selection of wild
type by use of AL therapy [17]. This adds to the evi-
dence that reduction in the drug pressure in malaria
parasites leads to re-emergence of wild type, which has
been documented [18]. The decline seen in Tanzania
seems to be similar to what was seen in Malawi but dif-
fers from what is seen in Kenya and Uganda, the imme-
diately neighbouring countries in the northern part of
Tanzania; this is attributed to continued use of certain
amounts of CQ in these countries [30]. In Gabon, the
prevalence of pfcrt mutations was reported to be high
more than five years after discontinued use of CQ [31].
Figure 2 Parasite clearance in 12 patients who had parasitaemia on day 2.
Table 3 PCR corrected and uncorrected cure rate
No % Prevalence PCR uncorrected No % Prevalence PCR corrected
ETF 0 0.0 0 0.0
LCF 3 2.9 0 0.0
LPF 2 1.9 1 1.0
ACPR 98 95.1 95 96
Total analysis 103 99
Withdrawal 2 4
Loss to follow-up 3
Total 108
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the inclusion of amodiaquine in artemisinin-based treat-
ment. There was however, a surprisingly high frequency
of mutations in pfcrt and pfmdr1 in subpatent re-infec-
tions found in follow-up samples. This contrasts with
most earlier studies, but a similar tendency for pfcrt is
observed in Ngasala et al, where at least no significant
difference in pfcrt frequencies were found in re-infec-
tions [29]. The remaining pfcrt and pfmdr1 mutations
indicates that it will be very difficult to completely
reverse CQ resistance once the resistance has been
established and reusing CQ may lead to rapid emer-
gence of CQ resistance. Any attempt to reuse CQ
should only be done under proper controls where the in
vitro susceptibility can be monitored.
On the other hand the prevalence of triple and double
pfdhfr mutants in Mwanza is very high 64.1% and 29.4%
compared to that reported previously in this area [3]. This
could be explained by the continued use of SP in IPTp
and probably in the treatment of malaria as the change of
policy from SP to ACT did not go hand in hand with the
ban of SP as occurred with CQ. The prevalence of triple
and double mutants in this place creates the doubt on the
usefulness of continued use of these drugs in IPTp but
also removes hope of the possibility of combining these
drugs with artemisinins. However, in re-infections lower
level of mutants were seen for pfdhfr and more dramati-
cally for pfdhps indicating a possible rapid return to SP
susceptibility with continued use of AL.
Conclusions
The efficacy of artemether-lumefantrine for treatment
of uncomplicated malaria was still high in the study
area although the rate of re-infection was high. There
was a high number of patients who got subpatent
malaria infection after treatment with ACT, which was
diagnosed by PCR later at day 14 or 28. The preva-
lence of pfcrt 76 K and pfmdr1 86 N was high in the
study area while markers for SP resistance shows that
the resistance to SP may still be very high and even
increasing. Artemether-lumefantrine may be selecting
for wild type alleles on both positions (437 and 540) of
pfdhps
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Table 4 Prevalence of mutations in pfcrt, pfmdr1, pfdhfr
and pfdhps in pre-treatment and post-treatment samples
Position (N) Mutants (n) Percentage P-value
Pfcrt 76
Pre-treatment (90) 10 11.1
Post-treatment (12) 4 33.3 0.22
Pfmdr1 86
Pre-treatment (95) 6 6.3
Post-treatment (19) 8 42.1 0.0000
Pfdhfr108
Pre-treatment (97) 92 94.8
Post-treatment (29) 21 74.2 0.0009
Pfdhfr 51
Pre-treatment (97) 73 75.3
Post-treatment (29) 20 69.0 0.025
Pfdhfr 59
Pre-treatment (97) 80 82.5
Post-treatment (29) 15 51.7 0.0000
Pfdhps 437 (N)
Pre-treatment (96) 71 74
Post-treatment (21) 7 33.3 0.0003
Pfdhps 540
Pre-treatment (95) 66 69.5
Post-treatment (21) 8 38.1 0.0000
Table 5 Prevalence of Pfdhfr mutations at position 108,
51, 59
N = 92 Pre-treatment n %
Triple mutants 59 64.1
Double mutants 108/51 10 10.9
Double mutants 108/59 2 2.2
Double mutants 59/51 1 1.1
Double mutants 108 with 59/51 and mix at third position 15 16.3
Single mutants 5 5.4
N = 23 Post-treatment
Triple mutants 13 56.5
Double mutants 108/51 2 8.7
Double mutants 108/59 2 8.7
Double mutants 59/51 0 0
Double mutants 108 with 59/51 and mix at third position 3 13.0
Single mutants 3 13.0
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